School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Kailera Therapeutics Inc KLRA

Healthcare · Biotechnology

$11.61last close 2026-10-09 · market cap $1.51B · delayed data

Trailing returns

1M-21.77%
3M-44.74%

Basis: Adjusted daily closes.

What it does

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.

Open KLRA in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies